| Name | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA |
| Description | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β . |
| Animal Research | Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy. |
| In vivo | Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight.?Haematoxylin and eosin tissue staining and blood biochemical examinations revealed no significant adverse effects following the two LSKL peptide administrations.?In the clinical setting, plasma TSP-1 levels were lowest on the first day after hepatectomy.?However, plasma TSP-1 levels at this stage were significantly higher in patients with subsequent liver dysfunction compared with levels in those without liver dysfunction following hepatectomy |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 27.5 mg/mL (40.05 mM)
|
| Keywords | LSKL, Inhibitor of Thrombospondin TSP1 acetate | LSKL, Inhibitor of Thrombospondin TSP 1 acetate | LSKL, Inhibitor of Thrombospondin TSP-1 Acetate |
| Inhibitors Related | Monocrotaline | SB-431542 | DMH-1 | RepSox | Chromenone 1 | BMP signaling agonist sb4 | Pirfenidone | A 83-01 | Galunisertib | Alantolactone |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Anti-Fibrosis Compound Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max | TGF-beta/Smad Compound Library |
United States
